Physician profile
Robert Lewis
NPI 1578031415
$6,506.37
in general payments reported to CMS, 2019-2025
50 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,016 · 2022: $1,500 · 2023: $1,344 · 2024: $537 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,990.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,287.47 | 2021 | |
| Abbvie INC. | $1,040.92 | 2021-2025 | |
| Novo Nordisk INC | $1,022.48 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $347.00 | 2021-2024 | Breztri, Farxiga |
| Lilly USA, LLC | $336.69 | 2021-2024 | Mounjaro, Zepbound |
| Harmony Biosciences LLC | $239.72 | 2022-2023 | Wakix |
| Sanofi-Aventis U.S. LLC | $152.49 | 2021-2024 | |
| Corium, LLC | $148.08 | 2022-2024 | Azstarys |
| Antares Pharma, INC. | $145.58 | 2021-2024 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $124.43 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $120.78 | 2021-2022 | |
| Pfizer INC. | $104.98 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.44 | 2021 | |
| Almatica Pharma LLC | $88.13 | 2021-2022 | |
| Eisai INC. | $78.06 | 2021-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.